for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Solid Biosciences Inc

SLDB.O

Latest Trade

6.36USD

Change

0.32(+5.30%)

Volume

633,378

Today's Range

5.91

 - 

6.50

52 Week Range

1.93

 - 

8.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.04
Open
6.05
Volume
633,378
3M AVG Volume
41.77
Today's High
6.50
Today's Low
5.91
52 Week High
8.55
52 Week Low
1.93
Shares Out (MIL)
60.45
Market Cap (MIL)
365.72
Forward P/E
-3.52
Dividend (Yield %)
--

Next Event

Solid Biosciences Inc Annual Shareholders Meeting

Latest Developments

More

Solid Biosciences Says Jennifer Ziolkowski, CFO Of Co Notified Co Of Her Intent To Resign

Solid Biosciences Inc Q3 Loss Per Share 44 Cents

Solid Biosciences Sees Existing Cash & Cash Equivalents To Fund Operating Expenses Into Q2 2021

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Solid Biosciences Inc

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Industry

Biotechnology & Drugs

Contact Info

141 Portland St Fl 5

CAMBRIDGE, MA

02139-1937

United States

+1.617.3374680

https://www.solidbio.com/

Executive Leadership

Ian F. Smith

Chairman of the Board

Ilan Ganot

President, Chief Executive Officer, Co-Founder, Director

Jennifer Ziolkowski

Chief Financial Officer, Treasurer

Joel Schneider

Chief Technology Officer and Head of Exploratory Research and Development

Carl Morris

Chief Scientific Officer

Key Stats

3.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-2.880

2018

-2.250

2019

-2.910

2020(E)

-1.714
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
12.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.51
LT Debt To Equity (MRQ)
2.60
Return on Investment (TTM)
-141.20
Return on Equity (TTM)
-115.24

Latest News

Latest News

Solid Biosciences says FDA lifts halt on gene therapy trial, shares soar

Solid Biosciences Inc said on Thursday the U.S. Food and Drug Administration (FDA) has lifted the clinical halt placed on a trial of its experimental gene therapy for Duchenne muscular dystrophy (DMD), a muscle-wasting disorder.

Solid Biosciences say FDA lifts halt on gene therapy trial

Solid Biosciences Inc said on Thursday the U.S. Food and Drug Administration (FDA) has lifted the clinical halt placed on a trial of its experimental gene therapy for a muscle-wasting disorder.

BRIEF-Solid Biosciences Announces Appointment Of Ian F. Smith As Chairman Of The Board Of Directors

* SOLID BIOSCIENCES ANNOUNCES APPOINTMENT OF IAN F. SMITH AS CHAIRMAN OF THE BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Solid Biosciences Says Board Appointed Ian Smith As Chairman

* SOLID BIOSCIENCES - ON JUNE 16, BOARD APPOINTED IAN SMITH AS CHAIRMAN - SEC FILING

BRIEF-Solid Biosciences Announces Appointment Of Ian F. Smith To Its Board

* SOLID BIOSCIENCES ANNOUNCES APPOINTMENT OF IAN F. SMITH TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Solid Biosciences Reports Q4 & Full Year 2019 Financial Results

* SOLID BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

UPDATE 1-Solid Biosciences medicines chief to step down, to cut workforce by one third

Solid Biosciences Inc said on Thursday its head of medicines would step down and that it would layoff one third of its workforce as the drug developer works to bring an end to the clinical halt on a trial of its experimental gene therapy.

Solid Biosciences to cut workforce, focus on DMD gene therapy

Solid Biosciences Inc said on Thursday it would cut its workforce by about one third and focus on its experimental gene therapy for muscle-wasting disorder Duchenne muscular dystrophy (DMD), after a trial of the treatment was halted in November.

Solid Biosciences shares plummet as gene therapy trial halted again

Shares in Solid Biosciences Inc plunged 71% on Tuesday after a trial testing its gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.

Solid Biosciences gene therapy trial put on hold by FDA

Solid Biosciences Inc said on Tuesday the U.S. Food and Drug Administration has put on hold a trial testing its gene therapy for a muscle-wasting disorder.

BRIEF-Boxer Capital Reports 6.2 Pct Passive Stake In Solid Biosciences

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SOLID BIOSCIENCES INC AS OF MAY 9 - SEC FILING Source text: (https://bit.ly/2GwS8zg) Further company coverage:

BRIEF-Solid Biosciences Reports Quarterly Loss Per Share Of $0.54

* SOLID BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

* SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Solid Biosciences Reports Full Year 2017 Financial Results And Provides Corporate Update

* SOLID BIOSCIENCES REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial

* SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Solid Biosciences Says Now Sees IPO Of 7 Mln Shares Of Common Stock Priced Between $18-$19/Shr - SEC Filing

* SOLID BIOSCIENCES LLC SAYS NOW SEES IPO OF 7.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $18.00 AND $19.00 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up